Despite Profit Surge, Novartis Still Suing to Prevent Lower Drug Prices | Common Dreams
www.commondreams.org
As Novartis released its third-quarter financial report, one watchdog pointed out that the Swiss pharmaceutical giant's profits have jumped from the same period last year but it is still suing over a 2022 law that cut prescription drug prices.